On February 11, the US Food and Drug Administration (FDA) approved brentuximab vedotin plus lenalidomide and rituximab for adults with relapsed or refractory large B-cell lymphoma who have undergone at least 2 lines of systemic therapy and are not candidates for autologous hematopoietic stem cell transplantation or CAR-T therapy. 

For more information, read the FDA announcement and the Pfizer press release.

Posted on 2/12/2025